The dual role of the COX-2/PGE2 Axis in multiple sclerosis: From pathogenesis to pharmacological inhibition

Clinical Immunology · Published 2025-11-22 · DOI 10.1016/j.clim.2025.110643

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.clim.2025.110643

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Immunometabolic reprogramming in multiple sclerosis: from pathogenic amplifier to therapeutic target in neuroinflammation and remyelination · Inflammopharmacology · 2026 · Cites or is cited by this article
• Decorin as a dynamic regulator in fibrosis: Mechanisms, therapeutic potential and future challenges · Clinical Immunology · 2026 · Same journal
• Monocytes from patients with chronic non-bacterial osteomyelitis (CNO) exhibit increased ‘classically activated’ phenotypes and altered DNA methylation patterns · Clinical Immunology · 2026 · Same journal
• A novel JAK1 mutation identified in a patient with severe atopic dermatitis phenotype: Mechanistic insights and IL-4Rα targeted therapy · Clinical Immunology · 2026 · Same journal
• The MENAT Region Inborn Errors of Immunity Research Consortium Registry (MENAT-IEI-RCR): Establishing a regional framework for collaborative research · Clinical Immunology · 2026 · Same journal
• Metabolic syndrome and increased inflammatory burden in active rheumatoid arthritis: An exploratory focus on hematologic markers · Clinical Immunology · 2026 · Same journal
• Salivary polyreactive and SARS-CoV-2-specific antibody responses following SARS-CoV-2 infection and vaccination in healthcare workers · Clinical Immunology · 2026 · Same journal
• CLIC1 acts as a compensatory protective molecule to regulate the vascular endothelial barrier integrity in cutaneous inflammation · Clinical Immunology · 2026 · Same journal
• Identification of a novel hypomorphic variant in CYBB underlying an adult presentation of X-linked recessive Mendelian susceptibility to mycobacterial disease · Clinical Immunology · 2026 · Same journal
• TGF-β1/TRAF-6 and IL-6/STAT-3 pathways in PSA-PSMA phenotypes of hormone-sensitive and hormone-refractory prostate Cancer · Clinical Immunology · 2026 · Same journal